Biotechnology company specializing on availing psychedelics medicine to market through novel delivery systems and psychedelic assisted psychotherapy Core One Labs Inc. (CSE: COOL) has officially started development of psychedelic drug formation for treatment of Alzheimer’s disease.
Core One Labs will be carrying out development of the psychedelic drug formulation through its wholly owned subsidiary Akome Biotech Ltd. Akome Bio is planning to conduct its preliminary analysis and data mapping of its bio-active psilocybin which will be used in advanced treatment of Alzheimer’s.
This formulation has been named ‘ALO002’ and it consists of psilocybin present in magic mushrooms and a plant bioactive.
Alzheimer’s disease is a progressive irreversible neurologic disease which damages a person’s thinking skills, memory and at last destroys their ability to perform single tasks.
Researchers believe that the two above ingredients are synergistic in treating the neurological disorder.
Core One Labs has already filed a provisional patent application for the candidate with the United States Patent and Trademark Office (USPTO).
